Business: DBV Technologies S.A. is a biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using the Viaskin electrostatic patch, which offers a convenient, self-administered, non-invasive immunotherapy to patients.